Objective: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).
A n abnormality in endothelium-dependent vasodilatation is a key phenomenon in patients with chronic heart failure (CHF). Numerous animal 1,2 and human 3, 4 studies demonstrated a significant improvement in endothelium-dependent relaxation by exercise training (ET). An important factor responsible for this improvement is the increase in the bioavailability of NO. Studies using cultured endothelial cells 5 (ECs) or vessel tissue specimens obtained from trained animals 6 or humans 7 clearly documented that an increase in shear stress resulted in activation of endothelial NO synthase (eNOS).
of HDL with respect to stimulation of NO production are significantly impaired in patients with diabetes, 13 coronary artery disease, 14 and primary antiphospholipid syndrome. 15 In these patients, malondialdehyde (MDA)-modified HDL may trigger the activation of PKC-βII, thereby reducing eNOS-dependent NO production. 14 These findings on the functional capacity of HDL in influencing endothelial function might promote a shift in therapeutic approaches targeting HDL from a mere increase in HDL concentration toward improving HDL function. 16 This view is further supported by the recently published dal-OUT-COMES trial, documenting that just increasing HDL level may not reduce the risk of recurrent cardiovascular events. 17 To assess the relation between disease severity of patients with CHF and HDL function, we isolated HDL from healthy controls and CHF patients in NYHA class II and IIIb and determined its ability to stimulate eNOS activation and thereby NO production. To study the impact of ET on HDL function, HDL was additionally isolated from healthy individuals and NYHA-IIIb patients after an ET program, and its stimulating effect on eNOS phosphorylation and NO production was evaluated.
Methods

Patient Population and Blood Sampling
Sixteen healthy control subjects with normal systolic left ventricle function (>55%), without signs or symptoms of CHF as well as evidence of coronary artery disease during coronary angiography, were included in the study. The healthy control subjects performed an ET program as outlined below for 4 weeks. In addition, 8 patients with CHF (LVEF <40%) in NYHA class II and 16 CHF patients in NYHA class IIIb were recruited. Patients in NYHA-IIIb were assigned to a 12-week ET program as outlined below.
Blood was collected from all subjects when entering the study and when finishing the ET program (only healthy and NYHA-IIIb subjects). Serum was prepared by centrifugation (10 minutes at 3000g at 4°C) and stored at −80°C until used.
Training Protocol
NYHA-IIIb. The initial phase of the exercise program was supervised and performed in-hospital. During the first 3 weeks, patients exercised 3 to 6 times daily for 5 to 20 minutes on a bicycle ergometer adjusted to the workload at which 50% of maximum oxygen uptake (VO 2 max) was reached. Before discharge from the hospital, symptom-limited spiroergometry was performed again to determine the training target heart rate for home-based training (defined as the heart rate reached at 60% of VO 2 max). On discharge, patients were provided with bicycle ergometers for home-based ET. They were encouraged to exercise close to their target heart rate for 20 to 30 minutes daily for a period of 12 weeks and were expected to participate in 1 supervised group training session for 60 minutes every week consisting of walking, calisthenics, and noncompetitive ball games.
Healthy Controls. The complete ET program was supervised and performed in-hospital. The participants exercised at 65% to 75% of VO 2 max during a period of 4 weeks (4 times 30 minutes per day, 5 days per week) on a bicycle ergometer. The total exercise time or exercise volume was not different between both groups.
Measurement of Endothelial Function
Flow-mediated dilatation of the radial artery was measured using a high-resolution ultrasound scanning echo-tracking angiometer (NIUS 02; Asulab Research Laboratory, Neuchatel, Switzerland). For detailed description, see Online Data Supplement.
Isolation of HDL
HDL was isolated from serum by sequential density ultracentrifugation (d=1.006-1.21 g/mL) as recently described in detail. 13, 14 For detailed description, see Online Data Supplement.
Cell Culture and Incubation With Isolated HDL
Human aortic ECs (HAEC; Cell Systems Biotechnology, Troisdorf, Germany) were cultured in EGM-2 cell culture medium (Lonza, Walkersville, MD) until 80% to 90% confluence. Cells were incubated for 0, 5, 10, 15, 30, or 60 minutes with 50 µg/mL isolated HDL. To elucidate signaling pathways, cells were pretreated (1 hour before HDL stimulation) with specific inhibitors such as rapamycin (20 nmol/L; Santa Cruz, Heidelberg, Germany) to inhibit p70S6K, or CG53353 (2 µmol/L; Merck Chemicals, Nottingham, United Kingdom) to inhibit PKC-βII. Thereafter, cells were harvested with ice-cold lysis buffer (50 mmol/L Tris-HCl; pH 7.4; 1% NP-40; 0.25% Na-deoxycholate; 150 mmol/L NaCl; 1 mmol/L EDTA; 0.1% Triton X-100; 0.2% SDS) containing protease inhibitor mix M (Serva, Heidelberg, Germany) as well as phosphatase inhibitor mix II (Serva). Protein concentration was determined using BSA as standard (BCA method; Pierce, Rockford, IL).
Western Blot Analysis
Ten micrograms of total protein was separated on a denaturing polyacrylamid gel and transferred to a PVDF membrane. To detect specific proteins, the following antibodies were applied: anti-eNOS (Santa Cruz), antiphospho-eNOS-Ser 1177 , antiphospho-eNOS-Thr 495 (both BD Biosciences, Heidelberg, Germany), anti-PKC-βII, antiphospho-PKC-βII-Ser 660 , anti-p70S6K, antiphospho p70S6Kα-Ser 411 (all Santa Cruz). For the evaluation of HDL-induced phosphorylation of the respective protein, the maximal stimulation was used. All samples were analyzed in triplicate.
Measurement of EC NO Production by ESR Spectroscopy
HAECs were incubated with HDL (50 µg/mL) for 60 minutes. NO production in HAEC was measured by ESR spectroscopy using the spin-probe colloid Fe(DETC) 2 . For detailed description, see Online Data Supplement.
Measurement of Paraoxonase-1 Enzymatic Activity
Paraoxonase (Pon) activity of HDL-associated paraoxonase-1 (PON1) was measured by spectrophotometry using paraoxon as substrate. 14
Quantification of Protein-Bound Malondialdehyd in HDL
Free and protein-bound MDA in HDL was detected by a commercially available lipid peroxidation assay kit (ALDetect; Enzo Life Sciences) as recommended by the manufacturer.
Measurement of Plasma Oxidative Capacity
Oxidative capacity was determined in plasma samples from all participants using a commercially available quantification kit (PerOx; KC5100; Immundiagnostik, Bensheim, Germany). Measurements were performed in duplicate. 
Nonstandard Abbreviations and Acronyms
NanoLC-MS/MS Analysis
The proteome of isolated HDL particles was investigated by shotgun LC-MS/MS analysis. 18 For detailed description, see Online Data Supplement.
Statistical Analysis
SPSS version 16.0 (SPSS Inc, Chicago, IL) was used for all the analyses. Data are expressed as means±SEM. Comparisons among groups were tested with ANOVA. When data were not normally distributed or the variance was not equal, the Kruskal-Wallis nonparametric test was used. A value of P<0.05 was considered statistically significant. All measurements were made by investigators blinded to the treatment group.
Results
Patient Characteristics and Follow-up After ET
The baseline values for all individuals included into the study are depicted in Online Table I . As expected, the healthy individuals significantly differed from patients with CHF with respect to left ventricle ejection fraction, maximal oxygen consumption, and medication. No difference was observed among the 3 groups comparing age, body mass index, arterial hypertension, and diabetes mellitus. None of the CHF patients were active smokers, whereas 3 healthy controls smoked at study beginning. On analyzing the lipid profile, a significantly lower HDL concentration was evident in CHF patients in NYHA class IIIb as compared with healthy individuals. The ET program of 12 weeks in NYHA class IIIb patients led to an increase of VO 2 max (14.9±0.6 to 16.8±0.9 mL/kg per minute; P<0.05) and left ventricular ejection fraction (26±1% to 32±2%; P<0.05). With respect to lipid profile, no change after 12 weeks of ET was evident. In the healthy controls, ET resulted in an increase in VO 2 max, a decrease in LDL, and an increase in HDL. All other parameters were unchanged.
HDL-Mediated eNOS Phosphorylation and NO Production: Impact of ET
Incubating HAECs with HDL healthy , phosphorylation of eNOS at position Ser 1177 was increased 4.7±0.4-fold versus unstimulated cells. This stimulation of eNOS-Ser 1177 phosphorylation was lower with HDL NYHA-II (3.7±1.1-fold versus unstimulated cells; P=NS versus healthy controls), reaching significantly lower values with HDL NYHA-IIIb compared with HDL healthy (1.7±0.2-fold versus unstimulated cells; P<0.001 versus healthy controls; Figure 1A ). Analyzing the eNOS phosphorylation at position Thr 495 , HDL NYHA-IIIb stimulated phosphorylation significantly more than by HDL healthy (NYHA-IIIb: 3.3±0.4-fold versus unstimulated cells; NYHA-II: 2.6±0.5-fold versus unstimulated cells; healthy controls: 1.5±0.4-fold versus unstimulated cells; P<0.05 NYHA-IIIb versus healthy controls; Figure 1B ). These differences in HDL-mediated eNOS phosphorylation capacity between the groups were also evident when measuring the HDL-induced NO production of ECs ( Figure 2 ).
Comparing the functional properties of HDL NYHA-IIIb before and after an exercise program revealed a significant improvement in phosphorylation of eNOS at position Ser 1177 (beginning: 1.7±0.2-fold versus unstimulated cells; end: 3.3±0.5-fold versus unstimulated cells; P<0.01; Figure 1A versus unstimulated cells; P<0.05; Figure 1B) , and a significantly higher production of NO in ECs (beginning: −1.0±3.3% increase versus buffer-treated cells; end: 19.4±7.5% increase versus buffer-treated cells; P<0.01; Figure 2 ). No significant impact of ET was observed in the healthy control group with respect to HDL-mediated eNOS-Ser 1177 phosphorylation (beginning: 4.7±0.4-fold versus unstimulated cells; end: 4.1±0.5-fold versus unstimulated cells; P=NS), eNOS-Thr 495 phosphorylation (beginning: 1.5±0.4-fold versus unstimulated cells; end: 1.5±0.3-fold versus unstimulated cells; P=NS; Figure 1A and 1B), and NO production ( Figure 2 ).
HDL-Mediated PKC-βII-Ser 660 Phosphorylation
Incubation of HAECs with HDL healthy resulted in a 1.4±0.3fold increase in PKC-βII phosphorylation at position Ser 660 as compared with unstimulated cells. The ability to stimulate PKC-βII phosphorylation was increased with increasing severity of CHF (NYHA-II: 1.8±1.1-fold versus unstimulated cells; NYHA-IIIb: 2.2±0.7-fold versus unstimulated cells; P<0.05 NYHA-IIIb versus healthy; Figure 3A ). In patients with CHF NYHA class IIIb, performing an exercise program significantly reduced the ability of HDL NYHA-IIIb to phosphorylate PKC-βII (beginning: 2.2±0.7 versus end: 1.4±0.2-fold versus unstimulated cells; P<0.05; Figure 3A ). No impact of ET on HDL-induced phosphorylation of PKC-βII was observed in healthy controls (beginning: 1.4±0.3 versus end: 1.6±0.2-fold versus unstimulated cells; P=NS; Figure 3A ). To evaluate the importance of PKC-βII activation for HDLinduced eNOS phosphorylation, the HDL NYHA-IIIb -induced eNOS phosphorylation at Ser 1177 and Thr 495 was measured in the absence or presence of a specific PKC-βII inhibitor (CG53353). As shown in Figure 3B , the inhibition of PKC-βII prevented HDL-induced phosphorylation at eNOS-Thr 495 without having any influence on eNOS-Ser 1177 phosphorylation.
HDL-Mediated p70S6K-Ser 411 Phosphorylation
Incubation of HAECs with HDL healthy resulted in a 1.5±0.2fold increase in p70S6K phosphorylation at position Ser 411 as compared with unstimulated cells. This ability to stimulate p70S6K phosphorylation was increased with increasing severity of CHF (NYHA-II: 1.9±0.4-fold versus unstimulated cells; NYHA-IIIb: 3.1±0.7-fold versus unstimulated cells; P<0.05 NYHA-IIIb versus healthy; Figure 4A ). In patients with CHF NYHA class IIIb, performing an exercise program significantly reduced the ability of HDL NYHA-IIIb to phosphorylate PKC-βII (beginning: 3.1±0.7 versus end: 1.4±0.1-fold versus unstimulated cells; P<0.01; Figure 4A ). No impact of ET on HDL-induced phosphorylation of PKC-βII was observed in healthy controls (beginning: 1.5±0.2 versus end: 1.7±0.2-fold versus unstimulated cells; P=NS; Figure 4A ).
Blocking PKC-βII activation by CG53353 resulted in an inhibition of HDL NYHA-IIIb -induced phosphorylation of p70S6K at Ser 411 ( Figure 4B ). In addition, blocking p70S6K activation by rapamycin prevented HDL NYHA-IIIb -induced phosphorylation of eNOS at Thr 495 without influencing eNOS phosphorylation at Ser 1177 ( Figure 4C and 4D).
MDA Bound to HDL
HDL-bound MDA was significantly increased in HDL NYHA-IIIb as compared with HDL healthy (healthy: 0.39±0.09 nmol/mg HDL; NYHA-II: 0.64±0.09 nmol/mg HDL; NYHA-IIIb: 1.13±0.10 nmol/mg HDL; P<0.001 healthy versus NYHA-IIIb; P<0.05 NYHA-II versus NYHA-IIIb; Figure 5A ). After finishing an ET program, the amount of HDL-bound MDA was significantly reduced by 27.4±6.1% in CHF-NYHA-IIIb, whereas no change was observed in healthy controls ( Figure 5B ).
PON-1 Enzyme Activity and Total Lipid Peroxides
Measuring the Pon enzymatic activity of PON-1 associated with isolated HDL, a significant decrease in HDL NYHA-IIIb was evident as compared with HDL healthy ( Figure 5C ). Although exercise intervention triggered a further increase in PON-1 activity of HDL healthy , it did not result in an improvement of low PON-1 activity observed for HDL NYHA-IIIb ( Figure 5C ).
Evaluating circulating total lipid peroxides as a measure for oxidative status, a significant higher level was obvious in the plasma of CHF NYHA-IIIb patients as compared with that of healthy controls (healthy: 151±41 versus NYHA-IIIb: 351±71 µmol/L; P<0.05). Furthermore, the ET intervention led to a significant reduction of total lipid peroxides (beginning NYHA-IIIb: 351±71 versus end: NYHA-IIIb: 210±54 µmol/L; P<0.05; Figure 5D ). No impact of ET on total lipid peroxides was evident in healthy controls ( Figure 5D ).
Correlation Between HDL and Endothelial Function
To investigate if the exercise-induced change in HDL function observed in CHF NYHA-IIIb patients has some influence on endothelial function, a correlation analysis between the change in HDL function and the observed change in endothelial function was performed. A significant correlation was evident between the change in HDL-induced eNOS-Ser 1177 phosphorylation (r=0.83; P<0.0001; Figure 6A ) or the absolute change in HDL-induced NO production (r=0.78; P<0.05; Figure 6B ) and the change in endothelial function. 
Proteome Analysis of HDL Particles
In LC-MS/MS analysis of HDL particles, 709 distinct peptides covering 134 distinct proteins were identified, applying a MASCOT cut-off ion score of >23 and a false discovery rate of <1%. We identified additional protein groups that have not been described in HDL particles before, such as β-Ala-His dipeptidase (CNDP1; Online Table II) . Differences in the proteomic profile of HDLs from healthy controls and CHF-NYHA-IIIb patients as well as effects of ET were visualized using a principal component analysis plot as indicator of variance in the data set (n=134 proteins; Figure 7A ) before and after ET. Because 41 proteins of the total data set of 134 proteins were only observed in 1 or a few samples, they might represent interindividual variation. Thus, detailed analyses of variations on individual proteins were focused on the remaining 93 proteins that were seen in all samples of the respective group (either patients/control or before/after ET).
t Tests were performed to reveal proteins that significantly differed in healthy controls and CHF-NYHA-IIIb patients either before or after ET. Volcano plots show the significance versus effect size change on the y and x axes, respectively, to visualize the most meaningful different proteins quickly ( Figure 7B and 7C) . The comparison of controls and NYHA patients before exercise revealed 13 proteins that differed in level between both groups ( Figure 7B ; red spots). After intervention, 17 proteins were present at different levels in controls and NYHA patients ( Figure 7C ; red spots; Online Table  I ). Additionally, t tests were performed to identify proteins influenced by ET either in the control or the patient group. However, for only 1 protein (Apolioprotein C-II), abundance levels were different in the healthy control group before and after exercise with a minor effect size (P<0.004; effect size of 0.19 indicates 1.15-fold change; Online Table I ). No ETdependent difference in individual proteins was observed for HDL NYHA-IIIb .
Discussion
In recent years, it became evident that not only the quantity, but also the functional capacity of HDL is important for influencing the risk of cardiovascular disease. 19 Therefore, strategies are being developed to increase HDL quantity and function. 16 ET is an accepted intervention strategy in patients with systolic heart failure, 20 and the molecular mechanisms behind the beneficial effect of ET have been described in part (for a detailed review, see Gielen et al 21 ) . With respect to functional properties of HDL in patients with CHF and the impact of ET, several findings emerge from the present study. First, the functional capacity of HDL to increase NO production in ECs via modulation of eNOS phosphorylation is impaired in patients with CHF. This functional incompetence is gradually increasing with disease severity. Second, in CHF patients, the amount of MDA bound to HDL is significantly elevated and the activation of PKC-βII/p70S6K by HDL NYHA-IIIb is significantly increased as compared with HDL healthy . Third, ET of CHF patients in NYHA-IIIb for 12 weeks significantly restored the functional capacity of HDL as well as the amount of MDA bound to HDL and the HDL-mediated activation of PKC-βII/p70S6K. The ET-induced change in HDL function significantly correlated with an improved endothelial function. Fourth, proteome analysis of the HDL particles revealed a clear distinction between HDL isolated from healthy controls and CHF NYHA-IIIb patients. No significant impact of ET on the overall protein composition of HDL particles was evident.
These findings suggest that ET has a positive effect on HDL function with respect to NO generation, and this might be one pathway how ET improves endothelial function in patients with CHF.
CHF and the Ability of HDL to Regulate NO Production
Experimental and clinical studies have suggested that eNOS-derived NO is a crucial determinant of vascular homeostasis, and reduced bioavailability of NO plays an important role in the development and progression of atherosclerosis. 22 Patients with CHF, irrespective of atherosclerotic etiology, are characterized by endothelial dysfunction as a result of increased oxidative stress and reduced NO bioavailability. 23 The activity of eNOS is regulated by intracellular calcium concentration, protein concentration per se, or by phosphorylation at specific residues via activation of protein kinase B or protein kinase A (for a detailed review, see Kolluru et al 24 ) . Besides the activation of eNOS by shear stress or agonists such as acetylcholine, bradykinin, or vascular endothelial growth factor, HDL also has the potency to activate eNOS by binding to the scavenger receptor-B1. 25 In the present study, we described, for the first time, that the capacity of HDL isolated from CHF patients to phosphorylate eNOS and generate NO is significantly impaired. This reduced ability of HDL to stimulate eNOS activity and NO production even seems to be related to disease severity, because the most relevant impairment was seen in CHF patients in NYHA class IIIb followed by patients in NYHA-II as compared with healthy controls. This result is in good agreement with findings in other atherosclerotic disorders. [13] [14] [15] This functional reduction of HDL is on top of a quantitative reduction of HDL, which was noted in patients described in the present Figure 5 . Quantification of protein-bound malondialdehyde (MDA) in high-density lipoprotein (HDL) isolated from healthy controls (healthy; n=8), chronic heart failure (CHF) patients in NYHA class II (NYHA-II; n=8), and CHF patients in NYHA class III (n=8; A) as well as the change after performing an exercise training program (B). PON1 paraoxonase activity was measured in HDL isolated from healthy controls (healthy) before (Beg.) and after an exercise training (ET) program (End), CHF patients in NYHA class II (NYHA-II), and CHF patients in NYHA class III at beginning (Beg.) and after finishing an ET program (End; C). In addition, the total amount of lipid peroxides as a measure for oxidative load was quantified in the plasma of all study participants (D). Values are expressed as means±SEM. December 6, 2013 study and in current literature, 26 resulting in a lower antiatherosclerotic effect of HDL.
Impact of ET on HDL Function
ET has been proven to correct endothelial dysfunction partially in a variety of diseases (for a review, see Gielen et al 21 ) . Restoration of NO bioavailability due to an increase in eNOS expression, a protein kinase B-mediated phosphorylation of eNOS at position Ser 1177 , and the reduction in ROS are discussed as molecular mechanisms. 7, 27 Using cultured human ECs and HDL NYHA-IIIb isolated before and after an ET intervention program, we could clearly demonstrate an improvement in HDL function, measured as the capacity to phosphorylate eNOS at Ser 1177 and Thr 495 , culminating in an increased NO production. The positive effect of ET on HDL function is in line with a study performed on overweight/obese men with cardiovascular risk factors where a low-fat diet combined with ET resulted in a lower HDL inflammatory index. 28 Unfortunately, the authors did not analyze the individual effects; it is not possible to differentiate which intervention, diet or ET, was responsible for the observed effect. Based on the results presented in this study, one may speculate that the training-induced increase in NO bioavailability and finally the improvement of endothelial function is partly because of an altered HDL function. This assumption is at least supported by the positive correlation between the exercise-induced change in HDL function (change in HDL-mediated phosphorylation of eNOS or HDLmediated NO production) and the change in endothelial function. This functional improvement of HDL by ET is realized without a change in total HDL concentration. This finding highlights an important point, namely, the functional competence of HDL may be more important for regulating endothelial function/antithrombotic function than the absolute amount.
Possible Molecular Mechanisms
As already described for HDL isolated from patients with stable coronary artery disease or an acute coronary syndrome, 14 HDL NYHA-IIIb significantly activated PKC-βII and subsequently p70S6K, thereby inhibiting protein kinase B-dependent regulation of eNOS. 29, 30 Inhibition studies using either CG53353 or rapamycin clearly documented that the activation of p70S6K is downstream of PKC-βII activation, and that HDL-mediated activation of this pathway influences mainly phosphorylation of eNOS at the inhibitory site Thr 495 . Of note, this activation of the PKC-βII pathway was significantly reduced in CHF patients after an ET program. A central question based on this observation is: what discriminates HDL isolated from healthy controls and patients with CHF in NYHA-IIIb in its ability to activate PKC-βII/p70S6K? At least 2 possibilities should be discussed: first, a change in the overall protein composition of the HDL particle; and second, a post-translational modification of the HDL particle. With respect to protein composition, a clear difference was evident between healthy controls and CHF-NYHA-IIIb patients. However, ET did not result in a drastic modification of the HDL proteome despite an improved HDL-mediated NO production. Second, another potential mechanism would be the modification of apolipoprotein A1 by reactive intermediates. Indeed, impaired HDL function after modification by MDA or myristic acid could be documented. [31] [32] [33] For example, MDA modification of HDL decreased cholesterol efflux from cultured human fibroblasts 31 or rat liver ECs. 32 Notably, in the present study, we observed that a significant higher level of MDA is bound to HDL NYHA-IIIb in comparison with HDL healthy , and that a training intervention significantly reduced the MDA amount bound to HDL NYHA-IIIb . Supported by in vitro studies, 14 it is reasonable to assume that the amount of MDA bound to HDL regulates the activation of PKC-βII (higher activation of PKC-βII in case more MDA is bound to HDL) and, finally, the activation of eNOS and NO generation. Because the modulation of HDL by MDA seems to play such a central role, the question that arises is: which factors are regulating the amount of MDA bound to HDL, and how are they influenced by ET? Pon, an enzyme associated with HDL, protects lipoproteins (HDL and LDL) from oxidative modification, and in clinical studies, a negative correlation between Pon activity and cardiovascular risk was confirmed. 34, 35 In the present study, Pon activity of HDL NYHA-IIIb was significantly decreased when compared with HDL healthy . However, ET had no effect on Pon activity. This is in accordance with a study performed in obese men, showing improved HDL inflammatory/anti-inflammatory properties after a lifestyle intervention without changing Pon activity. 28 Therefore, at the moment it remains unclear which mechanism beside Pon activity may be responsible for the ET-mediated reduction in MDA bound to HDL. Of note, an influence of ET on the total oxidative capacity, measured as lipid peroxides in the patient plasma, was evident. One may speculate that ET reduces the oxidative load and thereby reduces the amount of MDA bound to HDL.
Study Limitations
Some limitations of the present study should be mentioned.
First, only 16 NYHA-III patients or healthy individuals and 8 NYHA-II patients were included into the study. Nevertheless, the primary goal of this study was to investigate if HDL function in patients with CHF was altered and if this could be reversed by ET. Even with such a small number of individuals in each group, a significant impaired HDL function in NYHA-IIIb was evident, which could be improved by ET. Unfortunately, no data are available on the impact of ET in CHF patients in NYHA-class II, and we cannot rule out the impact of differences in medication background.
Second, it remains unclear which mechanism is responsible for the exercise-induced reduction of MDA bound to HDL. According to the data presented, the activity of paraoxogenase is not altered by ET and, therefore, can be excluded. However, we could observe an exercise-induced reduction in lipid peroxidation, which is a general measure for oxidative load. So far, it remains unclear which enzymatic system is responsible for the observed reduction in oxidative stress.
Third, currently we do not know if the alterations in HDL proteome observed between HDL healthy and HDL NYHA-IIIb have any causal relevance for HDL-mediated eNOS phosphorylation. To answer these questions, extensive studies using sitedirected mutagenesis are warranted. Because the proteome seems not to be influenced by ET, one may speculate that the HDL particle composition may not be as critical for HDLmediated eNOS regulation as the MDA bound to the HDL particle.
Fourth, the results presented are obtained in cell culture experiments using HDL isolated from frozen serum of different patient cohorts. Therefore, it has to be answered if this modulation of HDL also has an impact on endothelial function in vivo. At least the correlation detected between improved endothelial function induced by ET measured in vivo and HDL-associated change in eNOS phosphorylation and NO generation measured in vitro implies that this is an important mechanism for the regulation of endothelial function in vivo. With respect to serum storage at −80°C and functionality, no data with respect to HDL-mediated eNOS phosphorylation are available. Nevertheless, in a recent study investigating the HDL-mediated cholesterol efflux, no difference was detected between HDL isolated from fresh serum and serum stored for up to 2 years. 36 
Conclusions
In summary, the reduced ability of HDL to stimulate endothelial NO production via activation of eNOS in patients with advanced CHF suggests a loss of this functional property of HDL. An ET program in this patient cohort seems to correct this dysfunction partially. This may be one possible explanation, beside several others, for the beneficial effect of ET on Disease progression leads to a higher amount of malondialdehyde (MDA) bound to HDL, whereby PKC-βII gets more and more activated. This activation leads to an inhibition of HDL-mediated NO production because of a reduced endothelial NO synthase phosphorylation at eNOS-Ser 1177 and a higher phosphorylation at eNOS-Thr 495 . This process seems to be partially reversible by ET. December 6, 2013 endothelial function. The exercise-mediated effect on HDL function seems to be mediated via a reduction in MDA bound to HDL, leading finally to a lower activation of PKC-βII resulting in a higher activation of eNOS and a higher synthesis of NO (Figure 8 ).
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